These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 17418832

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
    Chaiyasit N, Taneepanichskul S.
    J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
    [Abstract] [Full Text] [Related]

  • 23. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol.
    Paoletti AM, Lello S, Fratta S, Orrù M, Ranuzzi F, Sogliano C, Concas A, Biggio G, Melis GB.
    Fertil Steril; 2004 Mar; 81(3):645-51. PubMed ID: 15037415
    [Abstract] [Full Text] [Related]

  • 24. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
    Ibáñez L, Valls C, Cabré S, De Zegher F.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4716-20. PubMed ID: 15356085
    [Abstract] [Full Text] [Related]

  • 25. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 26. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P.
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [Abstract] [Full Text] [Related]

  • 27. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome.
    Morgante G, Cappelli V, Troìa L, De Leo V.
    Eur J Contracept Reprod Health Care; 2020 Jun; 25(3):176-181. PubMed ID: 32191532
    [Abstract] [Full Text] [Related]

  • 29. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R.
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [Abstract] [Full Text] [Related]

  • 30. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [Abstract] [Full Text] [Related]

  • 31. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome.
    Bhattacharya SM, Jha A, DasMukhopadhyay L.
    Int J Gynaecol Obstet; 2016 Feb; 132(2):210-3. PubMed ID: 26613823
    [Abstract] [Full Text] [Related]

  • 32. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 33. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, Petracco A, Peixoto FC, Camargos AF.
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [Abstract] [Full Text] [Related]

  • 34. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
    Ibáñez L, De Zegher F.
    Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
    [Abstract] [Full Text] [Related]

  • 35. Use of an oral contraceptive containing drospirenone in an extended regimen.
    Sillem M, Schneidereit R, Heithecker R, Mueck AO.
    Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
    [Abstract] [Full Text] [Related]

  • 36. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP.
    J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
    [Abstract] [Full Text] [Related]

  • 38. [Effect on skin and hormonal hyperandrogenic manifestations of an oral estroprogestin association containing ethynilestradiol 30 mg and drospirenone 3 mg].
    Lello S, Primavera G, Colonna L, Vittori G, Guardianelli F, Pallotta P, Sorge R, Bilchugova E, Raskovic D.
    Minerva Ginecol; 2008 Jun; 60(3):239-43. PubMed ID: 18547986
    [Abstract] [Full Text] [Related]

  • 39. [Changes in plasma levels of androgens and SHBG in patients with polycystic ovary syndrome (PCOs) treated with oral contraceptives containing desogestrel].
    Negri P, D'Errico G, Minisci N, Tomasi A.
    Minerva Ginecol; 1988 Dec; 40(12):699-707. PubMed ID: 2977429
    [Abstract] [Full Text] [Related]

  • 40. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D, Borsos A, Baumgärtner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S.
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.